Thursday, June 04, 2015 9:17:19 AM
By Brittany Meiling Wednesday, June 3, 2015
Kleanthis Xanthopoulos
http://sdbj.com/news/2015/jun/03/regulus-ceo-apruptly-resigns-chief-science-officer/
Kleanthis Xanthopoulos
Kleanthis Xanthopoulos, who has served more than seven years at the helm of San Diego microRNA drug developer Regulus Therapeutics, unexpectedly resigned as CEO and from the company’s board, according to a statement from the company.
Xanthopoulos is leaving "to pursue investment opportunities in the biotechnology industry," Regulus said.
Chief Scientific Officer Neil Gibson is on his way out, too, leaving former Chief Medical Officer Paul Grint in the CEO spot.
The turnover comes at a pivotal point for Regulus, which is expecting crucial data on the microRNA hepatitis C therapy RG-101 later this year.
Xanthopoulos' surprise exit alarmed investors already wary of RG-101's rollercoaster clinical path so far, sending Regulus' shares down more than 20 percent.
The biotech, formed in 2007 with microRNA assets from Isis Pharmaceuticals and Alnylam Pharmaceuticals, is also working on preclinical candidates for cancer, fibrosis and metabolic disease alongside Big Pharma partners including GlaxoSmithKline, Sanofi and AstraZeneca.
Recent RGLS News
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/09/2024 08:54:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:27:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:15:41 PM
- Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates • PR Newswire (US) • 05/09/2024 08:05:00 PM
- Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 05/06/2024 12:00:00 PM
- Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series • PR Newswire (US) • 04/30/2024 12:00:00 PM
- Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates • PR Newswire (US) • 03/21/2024 08:05:00 PM
- Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity • PR Newswire (US) • 03/12/2024 10:32:00 AM
- Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 03/12/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 01:24:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 01:23:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:08:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:04:34 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/12/2024 09:11:34 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/10/2024 05:15:20 AM
- Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 01/02/2024 09:05:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/27/2023 09:16:06 PM
- Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference • PR Newswire (US) • 11/22/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:39:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:15:35 PM
- Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates • PR Newswire (US) • 11/09/2023 09:05:00 PM
- Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 11/02/2023 12:00:00 PM
- Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 10/19/2023 12:00:00 PM
- Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 09/20/2023 11:00:00 AM
- Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 09/13/2023 12:00:00 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM